German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...

German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.

German biotech company BioNTech announced a loss of EURO665.3 million (USD721 million) in 2024, due to the decline of ...